Browse Studies — Arctuva

Phase 1

A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias

This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are ref…

CardiovascularMetabolic DiseaseDyslipidemias+7 more

Estimated

~$10 – $8,750

CRISPR Therapeutics AGNCT07491172

Detection of Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors Exposed to Cisplatin-based Chemotherapy and Bone Marrow Transplant

Late subclinical cardiovascular disease in testicular cancer survivors exposed to cisplatin-based chemotherapy and bone marrow transplant

Testicular CancerSurvivorshipASCVD+5 more

Estimated

~$10 – $750

Indiana UniversityNCT05611307

Phase 2

Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) Trial

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology/American…

Lipid DisorderHypercholesterolemiaCardiovascular Diseases+1 more

Estimated

~$10 – $6,250

Wake Forest University Health SciencesNCT06488105

Lipoprotein Functions in Healthy Individuals and Subjects With Lipid Disorders

This study looks at how lipoproteins, which are particles in the blood that transport cholesterol, influence heart and blood vessel health. Beyond just their l…

Lipid Disorders

Estimated

~$10 – $750

The Miriam HospitalNCT06747000